NCT04714177

Edaravone Dexborneol for Treatment of Hypertensive Intracerebral Hemorrhage

Efficacy and Safety of Edaravone Dexborneol in Addition to Standard of Care in Patients With Hypertensive Intracerebral Hemorrhage: a Randomized, Double-Blind, Placebo-Controlled Trial

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 390 (estimated)
• Sponsor: First Affiliated Hospital, Sun Yat-Sen University · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

pending

Conditions

• Intracerebral Hemorrhage

Interventions

Type	Name	Description
DRUG	Edaravone Dexborneol	Edaravone Dexborneol 37.5 mg, containing Edaravone 30 mg and Dexborneol 7.5 mg, Edaravone Dexborneol 37.5 mg BID, 14 days, addition to standard of care of Intracerebral Hemorrhage
DRUG	Placebo	Edaravone Dexborneol matching injection, addition to standard of care of Intracerebral Hemorrhage

Timeline

• Start date: 2021-03-01
• Primary completion: 2023-03-01
• Completion: 2023-09-01
• First posted: 2021-01-19
• Last updated: 2021-01-19